AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material

News, Company News, Partnership

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
Follow Us
Join us on LinkedIn Follow us on Twitter